26Jan 2023
Therapeutic inertia related to the injectable glucagon‐like peptide‐1 receptor agonists dulaglutide and semaglutide in patients with type 2 diabetes in UK primary care

Therapeutic inertia related to the injectable glucagon‐like peptide‐1 receptor agonists dulaglutide and semaglutide in patients with type 2 diabetes in UK primary care

To determine the extent of therapeutic inertia related to the weekly injectable glucagon‐like peptide‐1 (GLP‐1) receptor agonists dulaglutide and semaglutide in patients with type 2 diabetes (T2D) in the UK. Multiple examples of therapeutic inertia were identified, including the first prescription at HbA1c levels considerably above target and failure to escalate to optimal doses even with evidence of suboptimal metabolic control. Therefore, a substantial proportion of patients did not achieve optimal HbA1c targets.

  • #endo-diabetology

Like

Save

Share